Dr. Robin Carhart-Harris speaks about the use of psilocybin for treatment-resistant depression.  
- Psilocybin, a psychedelic, is a 5-HT2A agonist.  Stimulation of the 5-HT2A receptor promotes neural plasticity
-A potential mechanism of action of psilocybin in treatment-resistant depression involves “brain resetting”
- Psilocybin has a good safety profile. However, patients may experience challenging psychological experiences that may turn out to be frightening for some people

Psilocybin for Treatment-Resistant Depression - Dr. Robin Carhart-Harris

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health & Fitness

In this episode, we discuss the prevalence of smoking among people with psychosis, based on recent findings from the PATH study. Dr. Oliver Freudenreich shares insights on how clinicians can prioritize smoking cessation in this population. How can we bridge the health outcome disparities faced by our patients with psychosis? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 55 Tobacco Use, Nicotine Dependence, and Cessation Among Adults with Psychosis 

Smoking and Psychosis: Insights from the PATH Study

In this episode, we delve into the use of clozapine for treatment-resistant psychosis and mood disorders. When should clinicians consider clozapine, and what do expert guidelines recommend? Dr. Brian Miller guides us through the evidence and best practices for utilizing this powerful but often underused medication. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.  Learn more about our memberships here Earn 1.25 CME: Clozapine: Management and Challenges Using Clozapine for Treatment-Resistant Psychosis and Mood Disorders 

Clozapine: The Gold Standard for Treatment-Resistant Schizophrenia

In this episode, we explore the role of lithium in treating pediatric bipolar disorder and conduct disorder. Is lithium a viable option for managing these complex conditions in children and adolescents, or are other medications more effective? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 14 Use of Lithium in Pediatric Bipolar Disorders and Externalizing Childhood-Related Disorders 

Balancing Benefits and Risks: Lithium in Child and Adolescent Psychiatry

In this episode, we explore real-world clinical cases demonstrating how broad-spectrum micronutrients can complement existing interventions for ADHD, emotional dysregulation, and mood instability. Can close monitoring and expert guidance optimize the integration of nutritional supplementation with pharmacologic treatments to create a harmonious, personalized approach? Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.75 CMEs: Broad-Spectrum Micronutrients (BSMs) for Mental Health: What You Need to Know for Clinical Use Clinical Cases 

Orchestrating Nutrition and Medication: Micronutrient Therapy in Practice

In this episode, we discuss the groundbreaking FDA approval of zuranolone, the first oral medication specifically targeting postpartum depression. Could zuranolone's novel mechanism of action as an allopregnanolone agonist herald a new era of rapid-onset, targeted treatments for this debilitating condition affecting 1 in 8 new mothers? Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 54 Zuranolone for the Treatment of Postpartum Depression 

Psilocybin for Treatment-Resistant Depression - Dr. Robin Carhart-Harris

Download our free app to listen on your phone